Re: Preliminary Results for Avelumab Plus Axitinib as First-Line Therapy in Patients with Advanced Clear-cell Renal-cell Carcinoma (JAVELIN Renal 100): An Openlabel, Dose-finding and Dose-expansion, Phase 1b Trial

Gruenwald Viktor; Hadaschik Boris

首页> 外文期刊>European urology >Re: Preliminary Results for Avelumab Plus Axitinib as First-Line Therapy in Patients with Advanced Clear-cell Renal-cell Carcinoma (JAVELIN Renal 100): An Openlabel, Dose-finding and Dose-expansion, Phase 1b Trial

【24h】

Re: Preliminary Results for Avelumab Plus Axitinib as First-Line Therapy in Patients with Advanced Clear-cell Renal-cell Carcinoma (JAVELIN Renal 100): An Openlabel, Dose-finding and Dose-expansion, Phase 1b Trial

机译：Re：Avelumab Plus Axitinib作为先进透明细胞肾细胞癌（标枪肾100）的一线治疗的初步结果：OpenLabel，剂量寻找和剂量扩展，第1B期试验

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European urology》 |2019年第4期|共3页
作者
Gruenwald Viktor; Hadaschik Boris;
展开▼
作者单位

Univ Hosp Essen West German Canc Ctr Interdisciplinary Genitourinary Oncol Hufelandstr 55 D;

Univ Hosp Essen Dept Urol Essen Germany;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类泌尿科学（泌尿生殖系疾病）;
关键词

相似文献

外文文献
中文文献

1. Re: Preliminary Results for Avelumab Plus Axitinib as First-Line Therapy in Patients with Advanced Clear-cell Renal-cell Carcinoma (JAVELIN Renal 100): An Openlabel, Dose-finding and Dose-expansion, Phase 1b Trial [J] . Gruenwald Viktor, Hadaschik Boris European urology . 2019,第4期

机译：Re：Avelumab Plus Axitinib作为先进透明细胞肾细胞癌（标枪肾100）的一线治疗的初步结果：OpenLabel，剂量寻找和剂量扩展，第1B期试验
2. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial [J] . Atkins Michael B., Plimack Elizabeth R., Puzanov Igor, The lancet oncology . 2018,第3期

机译：Axitinib与Pembrolizumab联合患者患有先进的肾细胞癌：非随机性，开放标签，剂量发现和剂量扩展阶段1B试验
3. Re: Michael B. Atkins, Elizabeth R. Plimack, Igor Puzanov, et al. Axitinib in Combination with Pembrolizumab in Patients with Advanced Renal Cell Cancer: A Non-randomised, Open-label, Dose-finding, and Dose-expansion Phase 1b Trial. Lancet Oncol 2018; 19: 405-15 [J] . Di Nunno Vincenzo, Santoni Matteo, Massari Francesco European urology . 2018,第2期

机译：回复：迈克尔B.阿特金斯，伊丽莎白r. plimack，igor puzanov等。 Axitinib与Pembrolizumab联合肾细胞癌症患者：非随机性，开放标签，剂量发现和剂量 - 膨胀期1B试验。柳叶刀oncol 2018; 19：405-15
4. Preliminary results of a phase I/II clinical trial using in situ photoimmunotherapy combined with imiquimod for metastatic melanoma patients [C] . Xiaosong Li, Mark F. Naylor, Robert E. Nordquist, . 2010

机译：使用原位光免疫疗法联合咪喹莫特治疗转移性黑色素瘤患者的I / II期临床试验的初步结果
5. Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial [O] . Hyun Cheol Chung, Hendrik-Tobias Arkenau, Jeeyun Lee, 2019

机译：Avelumab（anti-PD-L1）作为晚期胃癌或胃食管连接癌患者的一线开关维持或二线治疗：JAVELIN实体瘤试验的1b期结果
6. Randomized phase III trial of avelumab + axitinib vs sunitinib as first-line treatment for advanced renal cell carcinoma: JAVELIN renal 101 Japanese subgroup analysis [O] . M. Uemura, Y. Tomita, H. Miyake, 2019

机译：Avelumab + Axitinib的随机期III试验VS Sunitinib作为晚期肾细胞癌的一线治疗：Javelin肾101日本亚组分析

Re: Preliminary Results for Avelumab Plus Axitinib as First-Line Therapy in Patients with Advanced Clear-cell Renal-cell Carcinoma (JAVELIN Renal 100): An Openlabel, Dose-finding and Dose-expansion, Phase 1b Trial

著录项

相似文献

相关主题

期刊订阅